the need for more effective, less toxic therapies in frontline dlbcl treatment
Published 1 year ago • 221 plays • Length 2:18Download video MP4
Download video MP3
Similar videos
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
0:42
targeted therapies for dlbcl treatment
-
1:36
the future of frontline treatment in all: immunotherapy
-
2:27
the importance of balancing efficacy & toxicity when selecting treatment approaches in frontline hl
-
1:58
incorporating immunotherapy in the frontline & salvage treatment of hodgkin lymphoma
-
1:09:24
update on immunotherapy in the treatment of lymphoma | lrf webinars
-
10:07
understanding diffuse large b-cell lymphoma with bruce cheson, md, facp, faaas, fasco
-
29:38
dlbcl treatment approaches: what you need to know
-
1:33
addressing the potential role of immunotherapy in the frontline treatment of all
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
3:04
applying molecular understanding of dlbcl to management strategies
-
1:15
personalized medicine for dlbcl
-
1:28
novel ultra-sensitive mrd profiling tool predicts outcomes in dlbcl after frontline treatment
-
1:32
current trials of non-cytotoxic therapies for older all
-
0:37
immune checkpoint inhibitors: shaping the future of lymphoma
-
0:44
risk of transformation by frontline management in fl and mzl: a us population-based analysis
-
1:55
novel biological therapies for managing non-hodgkin lymphoma
-
1:11
exciting updates in all and the value of novel immunotherapies
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
1:30
the use of targeted drug therapy for aggressive lymphoma
-
10:51
update of targeted or chemotherapy-free therapies in lymphoma
-
3:21
safety management of car-t cell therapy in dlbcl